vs
Centuri Holdings, Inc.（CTRI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Centuri Holdings, Inc.的季度营收约是Revvity的1.1倍（$858.6M vs $772.1M），Revvity净利率更高（12.7% vs 3.5%，领先9.2%），Centuri Holdings, Inc.同比增速更快（19.7% vs 5.9%），Revvity自由现金流更多（$161.8M vs $66.3M），过去两年Centuri Holdings, Inc.的营收复合增速更高（27.5% vs 9.0%）
Centuri Holdings前身为Allied Leisure，是美国街机游戏制造商，总部位于佛罗里达州海厄利亚。20世纪80年代初，它是美国排名前六的投币式街机视频游戏设备供应商之一。1980年，原Taito美国总裁埃德·米勒与合伙人比尔·奥利吉斯收购Allied Leisure后，将其更名为Centuri。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CTRI vs RVTY — 直观对比
营收规模更大
CTRI
是对方的1.1倍
$772.1M
营收增速更快
CTRI
高出13.9%
5.9%
净利率更高
RVTY
高出9.2%
3.5%
自由现金流更多
RVTY
多$95.5M
$66.3M
两年增速更快
CTRI
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $858.6M | $772.1M |
| 净利润 | $30.4M | $98.4M |
| 毛利率 | 9.4% | — |
| 营业利润率 | 4.3% | 14.5% |
| 净利率 | 3.5% | 12.7% |
| 营收同比 | 19.7% | 5.9% |
| 净利润同比 | 194.1% | 3.9% |
| 每股收益（稀释后） | $0.34 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTRIRVTY
| Q4 25 | $858.6M | $772.1M | ||
| Q3 25 | $850.0M | $698.9M | ||
| Q2 25 | $724.1M | $720.3M | ||
| Q1 25 | $550.1M | $664.8M | ||
| Q4 24 | $717.1M | $729.4M | ||
| Q3 24 | $720.1M | $684.0M | ||
| Q2 24 | $672.1M | $691.7M | ||
| Q1 24 | $528.0M | $649.9M |
净利润CTRIRVTY
| Q4 25 | $30.4M | $98.4M | ||
| Q3 25 | $2.1M | $46.7M | ||
| Q2 25 | $8.1M | $53.9M | ||
| Q1 25 | $-17.9M | $42.2M | ||
| Q4 24 | $10.3M | $94.6M | ||
| Q3 24 | $-3.7M | $94.4M | ||
| Q2 24 | $11.7M | $55.4M | ||
| Q1 24 | $-25.1M | $26.0M |
毛利率CTRIRVTY
| Q4 25 | 9.4% | — | ||
| Q3 25 | 9.2% | 53.6% | ||
| Q2 25 | 9.4% | 54.5% | ||
| Q1 25 | 3.7% | 56.5% | ||
| Q4 24 | 9.9% | — | ||
| Q3 24 | 10.5% | 56.3% | ||
| Q2 24 | 9.0% | 55.7% | ||
| Q1 24 | 2.5% | 54.6% |
营业利润率CTRIRVTY
| Q4 25 | 4.3% | 14.5% | ||
| Q3 25 | 4.3% | 11.7% | ||
| Q2 25 | 4.4% | 12.6% | ||
| Q1 25 | -2.3% | 10.9% | ||
| Q4 24 | 4.7% | 16.3% | ||
| Q3 24 | 5.8% | 14.3% | ||
| Q2 24 | 4.9% | 12.4% | ||
| Q1 24 | -4.2% | 6.8% |
净利率CTRIRVTY
| Q4 25 | 3.5% | 12.7% | ||
| Q3 25 | 0.2% | 6.7% | ||
| Q2 25 | 1.1% | 7.5% | ||
| Q1 25 | -3.3% | 6.4% | ||
| Q4 24 | 1.4% | 13.0% | ||
| Q3 24 | -0.5% | 13.8% | ||
| Q2 24 | 1.7% | 8.0% | ||
| Q1 24 | -4.7% | 4.0% |
每股收益（稀释后）CTRIRVTY
| Q4 25 | $0.34 | $0.86 | ||
| Q3 25 | $0.02 | $0.40 | ||
| Q2 25 | $0.09 | $0.46 | ||
| Q1 25 | $-0.20 | $0.35 | ||
| Q4 24 | $0.17 | $0.77 | ||
| Q3 24 | $-0.04 | $0.77 | ||
| Q2 24 | $0.14 | $0.45 | ||
| Q1 24 | $-0.35 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $126.6M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $873.0M | $7.3B |
| 总资产 | $2.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTRIRVTY
| Q4 25 | $126.6M | $919.9M | ||
| Q3 25 | $16.1M | $931.4M | ||
| Q2 25 | $28.3M | $991.8M | ||
| Q1 25 | $15.3M | $1.1B | ||
| Q4 24 | $49.0M | $1.2B | ||
| Q3 24 | $52.5M | $1.2B | ||
| Q2 24 | $30.9M | $2.0B | ||
| Q1 24 | $18.4M | $1.7B |
股东权益CTRIRVTY
| Q4 25 | $873.0M | $7.3B | ||
| Q3 25 | $585.2M | $7.4B | ||
| Q2 25 | $567.1M | $7.6B | ||
| Q1 25 | $536.5M | $7.6B | ||
| Q4 24 | $555.6M | $7.7B | ||
| Q3 24 | $527.3M | $7.9B | ||
| Q2 24 | $530.4M | $7.9B | ||
| Q1 24 | $197.8M | $7.8B |
总资产CTRIRVTY
| Q4 25 | $2.4B | $12.2B | ||
| Q3 25 | $2.2B | $12.1B | ||
| Q2 25 | $2.1B | $12.4B | ||
| Q1 25 | $2.0B | $12.4B | ||
| Q4 24 | $2.1B | $12.4B | ||
| Q3 24 | $2.1B | $12.8B | ||
| Q2 24 | $2.2B | $13.4B | ||
| Q1 24 | $2.1B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $83.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $66.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 7.7% | 21.0% |
| 资本支出强度资本支出/营收 | 2.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.76× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-8.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CTRIRVTY
| Q4 25 | $83.9M | $182.0M | ||
| Q3 25 | $5.2M | $138.5M | ||
| Q2 25 | $-27.7M | $134.3M | ||
| Q1 25 | $16.7M | $128.2M | ||
| Q4 24 | $61.0M | $174.2M | ||
| Q3 24 | $180.2M | $147.9M | ||
| Q2 24 | $-56.6M | $158.6M | ||
| Q1 24 | $-26.5M | $147.6M |
自由现金流CTRIRVTY
| Q4 25 | $66.3M | $161.8M | ||
| Q3 25 | $-18.4M | $120.0M | ||
| Q2 25 | $-48.5M | $115.5M | ||
| Q1 25 | $-7.7M | $112.2M | ||
| Q4 24 | $27.8M | $149.8M | ||
| Q3 24 | $160.7M | $125.6M | ||
| Q2 24 | $-76.9M | $136.6M | ||
| Q1 24 | $-52.7M | $129.7M |
自由现金流率CTRIRVTY
| Q4 25 | 7.7% | 21.0% | ||
| Q3 25 | -2.2% | 17.2% | ||
| Q2 25 | -6.7% | 16.0% | ||
| Q1 25 | -1.4% | 16.9% | ||
| Q4 24 | 3.9% | 20.5% | ||
| Q3 24 | 22.3% | 18.4% | ||
| Q2 24 | -11.4% | 19.7% | ||
| Q1 24 | -10.0% | 20.0% |
资本支出强度CTRIRVTY
| Q4 25 | 2.0% | 2.6% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 2.9% | 2.6% | ||
| Q1 25 | 4.4% | 2.4% | ||
| Q4 24 | 4.6% | 3.4% | ||
| Q3 24 | 2.7% | 3.3% | ||
| Q2 24 | 3.0% | 3.2% | ||
| Q1 24 | 5.0% | 2.7% |
现金转化率CTRIRVTY
| Q4 25 | 2.76× | 1.85× | ||
| Q3 25 | 2.48× | 2.97× | ||
| Q2 25 | -3.43× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 5.90× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | -4.84× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTRI
| Master Services Agreement | $660.7M | 77% |
| Non Union Electric Segment | $163.4M | 19% |
| Related Party | $25.6M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
